This post was originally published on this site

BidaskClub upgraded shares of AxoGen (NASDAQ:AXGN) from a buy rating to a strong-buy rating in a research report report published on Saturday morning, BidAskClub reports.

A number of other equities research analysts also recently weighed in on AXGN. Guggenheim began coverage on AxoGen in a research report on Thursday, October 22nd. They set a buy rating and a $24.00 target price on the stock. Canaccord Genuity reaffirmed a hold rating and set a $13.00 price objective on shares of AxoGen in a report on Wednesday, September 16th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $17.13.

NASDAQ AXGN opened at $19.57 on Friday. The firm has a market cap of $785.27 million, a P/E ratio of -31.06 and a beta of 0.71. The stock’s 50-day moving average is $16.76 and its two-hundred day moving average is $13.29. AxoGen has a fifty-two week low of $7.16 and a fifty-two week high of $20.83. The company has a debt-to-equity ratio of 0.42, a current ratio of 7.45 and a quick ratio of 6.81.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Tuesday, November 3rd. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.18. The company had revenue of $33.43 million for the quarter, compared to the consensus estimate of $30.10 million. AxoGen had a negative return on equity of 19.83% and a negative net margin of 22.98%. On average, equities analysts expect that AxoGen will post -0.61 EPS for the current year.

In other news, CFO Peter J. Mariani sold 75,683 shares of AxoGen stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $12.41, for a total value of $939,226.03. Following the completion of the transaction, the chief financial officer now owns 80,683 shares in the company, valued at $1,001,276.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Karen L. Zaderej sold 3,500 shares of AxoGen stock in a transaction that occurred on Tuesday, December 29th. The shares were sold at an average price of $17.81, for a total transaction of $62,335.00. The disclosure for this sale can be found here. Insiders sold 129,232 shares of company stock valued at $1,750,190 in the last quarter. 6.94% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the stock. Envestnet Asset Management Inc. raised its position in AxoGen by 2.1% in the 3rd quarter. Envestnet Asset Management Inc. now owns 46,015 shares of the medical equipment provider’s stock worth $535,000 after purchasing an additional 938 shares during the last quarter. California Public Employees Retirement System raised its position in shares of AxoGen by 2.3% during the 3rd quarter. California Public Employees Retirement System now owns 75,300 shares of the medical equipment provider’s stock valued at $876,000 after acquiring an additional 1,700 shares during the last quarter. American International Group Inc. grew its holdings in shares of AxoGen by 10.8% in the 2nd quarter. American International Group Inc. now owns 22,257 shares of the medical equipment provider’s stock valued at $206,000 after buying an additional 2,177 shares during the period. California State Teachers Retirement System grew its holdings in shares of AxoGen by 5.3% in the 3rd quarter. California State Teachers Retirement System now owns 54,879 shares of the medical equipment provider’s stock valued at $638,000 after buying an additional 2,768 shares during the period. Finally, Advisor Group Holdings Inc. grew its holdings in shares of AxoGen by 113.7% in the 2nd quarter. Advisor Group Holdings Inc. now owns 6,226 shares of the medical equipment provider’s stock valued at $58,000 after buying an additional 3,313 shares during the period. Hedge funds and other institutional investors own 78.38% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Further Reading: Why is the price-sales ratio important?

Analyst Recommendations for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AxoGen and related companies with MarketBeat.com’s FREE daily email newsletter.